//fpnotebook.com/
Ophthalmic Cyclosporine
Aka: Ophthalmic Cyclosporine, Ophthalmic Calcineurin Inhibitor, Restasis, Cyclosporine Ophthalmic Emulsion, Cyclosporine Ophthalmic Suspension- See Also
- Indications
- Mechanism
- Cyclosporine is a Calcineurin Inhibitor with Immunosuppression and antiinflammatory properties (esp. inhibits T-Helper Cells)
- Improves tear production in autoimmune disorders (esp. Sjogren's Syndrome)
- Preparations
- Cyclosporine A 0.05% (Restasis) use 1 drop in each eye every 12 hours
- Wait for 10 minutes before inserting Contact Lenses after applying drop
- Cyclosporine A 0.05% (Restasis) use 1 drop in each eye every 12 hours
Medication Costs | ||
---|---|---|
restasis (on 5/17/2017 at Medicaid.Gov Pharmacy Drug pricing) | ||
RESTASIS 0.05% EYE EMULSION | $7.45 each | |
RESTASIS MULTIDOSE 0.05% EYE | $80.48 per ml | |
FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. |
Cyclosporine 0.5 MG/ML Ophthalmic Suspension (C1168858) |
|
---|---|
Concepts | Clinical Drug (T200) |
SnomedCT | 407103000 |
English | CYCLOSPORINE 0.05 % OPHTHALMIC DROPPERETTE, SINGLE-USE DROP DISPENSER, CYCLOSPORINE@0.05 %@OPHTHALMIC@DROPPERETTE, SINGLE-USE DROP DISPENSER, Cyclosporine 0.5 MG/ML Ophthalmic Suspension, CYCLOSPORINE 0.05% (PF) OPH EMUL 0.4ML, cyclosporine 0.05 % Ophthalmic Suspension, CYCLOSPORINE 0.05% OPHTHALMIC DROPPERETTE, SINGLE-USE DROP DISPENSER, CYCLOSPORINE@0.05%@OPHTHALMIC@DROPPERETTE, SINGLE-USE DROP DISPENSER, CYCLOSPORINE 0.05% DROPPERETTE, SINGLE-USE DROP DISPENSER, CYCLOSPORINE @ 0.05% @ DROPPERETTE, SINGLE-USE DROP DISPENSER, CYCLOSPORINE 0.05% (PF) EMULSION,OPH,0.4ML [VA Product], Cyclosporine 0.05% Ophthalmic drops, emulsion, cycloSPORINE 0.05 % Ophthalmic Suspension, cycloSPORINE 0.5 MG/ML Ophthalmic Suspension, Cyclosporine 0.05% Ophthalmic Emulsion, Cyclosporine (Ophth) Emulsion 0.05%, Cyclosporine ophthalmic emulsion 0.05% (product), Cyclosporine ophthalmic emulsion 0.05%, cycloSPORINE ophthalmic 0.05% ophthalmic emulsion, CYCLOSPORINE 0.05% (PF) EMULSION,OPH,0.4ML |
Spanish | ciclosporina, 0,05%, emulsión oftálmica (producto), ciclosporina, 0,05%, emulsión oftálmica |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Restasis (C1170584) |
|
---|---|
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
English | Restasis, restasis |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Cyclosporine Ophthalmic Emulsion (C2699534) |
|
---|---|
Definition (NCI) | An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti-inflammatory activities. The exact therapeutic mechanism of action of cyclosporine is not known but may involve binding to the cellular protein cytophilin, resulting in inhibition of the enzyme calcineurin. This agent appears to specifically and reversibly inhibit immunocompetent lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are preferentially inhibited with T-helper cells as the primary target. Cyclosporine also inhibits lymphokine production and release. |
Concepts | Pharmacologic Substance (T121) |
English | Cyclosporine Ophthalmic Emulsion |
Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.
If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.
Please Contact Me as you run across problems with any of these versions on the website.